EMD Chemicals Signs License with Luminex to Develop Assays for xMAP | GenomeWeb
NEW YORK (GenomeWeb News) - Luminex has granted EMD Chemicals, a subsidiary of Germany’s Merck KGaA, a license to develop multiplex immunoassays for the xMAP technology platform, EMD said last week.
EMD said it plans to develop multiplex assays for the xMAP under its Novagen brand to detect the phosphorylation status of proteins in disease-related signaling pathways.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.